2. Search Result
Search Result
Results for "

Glutamate Antagonist

" in MedChemExpress (MCE) Product Catalog:

73

Inhibitors & Agonists

2

Peptides

8

Natural
Products

17

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-20167A
    H-Glu(OtBu)-OtBu hydrochloride

    		Neurokinin Receptor Neurological Disease
    H-Glu(OtBu)-OtBu hydrochloride is a glutamate derivative that can be used for substance P antagonist synthesis .
    H-Glu(OtBu)-OtBu hydrochloride
  • HY-108690
    Fluxametamide
    2 Publications Verification

    		 GABA Receptor Others
    Fluxametamide is an insecticide with wide spectrum, acts as an antagonist of GABA- and glutamate-gated chloride channels, with IC50 of 1.95 nM and 225 nM for M. domestica GABACls and GluCls.
    Fluxametamide
  • HY-101356
    CPCCOEt

    		mGluR Neurological Disease
    CPCCOEt is a low affinity, selective, non-competitive and reversible antagonist of metabotropic glutamate receptor 1b (mGluR1b) .
    CPCCOEt
  • HY-101375
    (RS)-APICA

    		mGluR Neurological Disease
    (RS)-APICA is a selective group II metabotropic glutamate receptor (mGluR II) antagonist. (RS)-APICA shows potential neuroprotective effect .
    (RS)-APICA
  • HY-100821
    2,4-Dihydroxyphenylacetylasparagine

    		Bacterial Infection
    2,4-Dihydroxyphenylacetylasparagine is a potent and selective antagonist of glutamate. 2,4-Dihydroxyphenylacetylasparagine inhibits glutamate binding to rat brain synaptic membranes .
    2,4-Dihydroxyphenylacetylasparagine
  • HY-101809
    CNS-5161 hydrochloride

    CNS 5161A

    		 iGluR Cardiovascular Disease
    CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS-5161 hydrochloride
  • HY-101226
    MSOP

    		mGluR Neurological Disease
    MSOP is a selective group III metabotropic glutamate receptor antagonist with apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR.
    MSOP
  • HY-101809A
    CNS 5161

    		iGluR Cardiovascular Disease
    CNS-5161 is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS 5161
  • HY-100743
    DL-AP4

    2-Amino-4-phosphonobutyric acid

    		 Others Neurological Disease Metabolic Disease
    DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system .
    DL-AP4
  • HY-100405
    FTIDC

    		mGluR Neurological Disease
    FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC50 of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1 .
    FTIDC
  • HY-108546
    L-AP3

    3-Phosphono-L-alanine

    		 mGluR Neurological Disease
    L-AP3, metabotropic glutamate receptor (mGluR) antagonist, inhibits D-phosphoserine and L-phosphoserine with IC50s of 368 μM and 2087 μM, respectively .
    L-AP3
  • HY-103232
    IEM-1925 bromide

    		mGluR Neurological Disease
    IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .
    IEM-1925 bromide
  • HY-15072
    Zonampanel

    YM 872

    		 iGluR Metabolic Disease
    Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.
    Zonampanel
  • HY-107512
    Kynurenic acid sodium
    3 Publications Verification

    		 iGluR Apoptosis Endogenous Metabolite CXCR GPR35 Neurological Disease Inflammation/Immunology Endocrinology
    Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
    Kynurenic acid sodium
  • HY-100806
    Kynurenic acid
    3 Publications Verification

    Quinurenic acid

    		 iGluR Endogenous Metabolite Apoptosis CXCR GPR35 Neurological Disease Inflammation/Immunology Endocrinology
    Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
    Kynurenic acid
  • HY-101311
    UPF-523

    AIDA

    		 mGluR Inflammation/Immunology
    UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a) with an IC50 of 214 μM. But UPF-523 has no effect on group II (mGlu2), group III (mGlu4) receptors or ionotropic glutamate receptors. UPF-523 has the potential for the research of the acute arthritis .
    UPF-523
  • HY-15067
    DNQX
    4 Publications Verification

    FG 9041

    		 iGluR Cancer
    DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
    DNQX
  • HY-19168
    Perzinfotel

    EAA-090

    		 iGluR Neurological Disease
    Perzinfotel (EAA-090) is a potent, selective, and competitive NMDA receptor antagonist with neuroprotective effects. Perzinfotel (EAA-090) shows high affinity (IC50=30 nM) for the glutamate site .
    Perzinfotel
  • HY-103568
    YM-298198 hydrochloride

    		mGluR Neurological Disease
    YM-298198 hydrochloride is a high-affinity, selective, orally active, and non-competitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders .
    YM-298198 hydrochloride
  • HY-100714A
    D-AP5
    15+ Cited Publications

    D-APV; D-2-Amino-5-phosphonovaleric acid

    		 iGluR Neurological Disease
    D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors .
    D-AP5
  • HY-131289
    LY3020371

    		mGluR Neurological Disease
    LY3020371 is a potent and selective antagonist of glutamate (mGlu) 2/3 receptor, with Kis of 5.26 and 2.50 nM for hmGluR2 and hmGluR3, respectively. LY3020371 can be used for the research of depression .
    LY3020371
  • HY-103233
    DNQX disodium salt

    FG 9041 disodium salt

    		 iGluR Cancer
    DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
    DNQX disodium salt
  • HY-106467B
    Caroverine hydrochloride

    Tinnex hydrochloride

    		 iGluR Neurological Disease
    Caroverine (Tinnex) hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .
    Caroverine hydrochloride
  • HY-103570
    MCPG sodium

    		mGluR Neurological Disease
    MCPG is a carboxylic phenyl glycine. MCPG can block metabotropic glutamate receptor (mGluR)(HY-15129) and has antagonistic activity of mGluR subtype. MCPG can be used to study the induction and maintenance of long-term potentiation (LTP) .
    MCPG sodium
  • HY-125717
    VU0029251

    		mGluR Neurological Disease
    VU0029251 is a mGluR5 partial antagonist (Ki: 1.07 μM). VU0029251 inhibits glutamate induced calcium mobilization in HEK293 cell membranes expressing rat mGluR5 (IC50: 1.7 μM) .
    VU0029251
  • HY-100372
    E4CPG

    (RS)-ECPG

    		 mGluR Neurological Disease
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation .
    E4CPG
  • HY-100406
    (S)-MCPG
    1 Publications Verification

    (+)-MCPG

    		 mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .
    (S)-MCPG
  • HY-102094
    (E/Z)-SIB-1893

    		mGluR Neurological Disease
    (E/Z)-SIB-1893 is a racemic compound of (E)-SIB-1893 and (Z)-SIB-1893 isomers. (E)-SIB-1893 is a selective non-competitive metabotropic glutamate subtype 5 receptor (mGluR5) antagonist .
    (E/Z)-SIB-1893
  • HY-103563
    3-MATIDA

    		Others Neurological Disease
    3-MATIDA is a metabolic glutamate 1 (mGlu1) receptor antagonist. 3-MATIDA alleviates neuronal death in cerebral ischemia models. 3-MATIDA can be used in the study of neuronal injury and epileptiform activity after ischemia .
    3-MATIDA
  • HY-17412
    Minocycline hydrochloride
    Maximum Cited Publications
    35 Publications Verification

    		 Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .
    Minocycline hydrochloride
  • HY-17412A
    Minocycline

    		Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .
    Minocycline
  • HY-100371
    (RS)-MCPG
    1 Publications Verification

    alpha-MCPG

    		 mGluR Neurological Disease
    (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons .
    (RS)-MCPG
  • HY-123820
    LY3020371 hydrochloride

    		mGluR Neurological Disease
    LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM . LY3020371 hydrochloride exerts an antidepressant-like signature in vivo .
    LY3020371 hydrochloride
  • HY-103551A
    LY 541850

    		mGluR Neurological Disease
    LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively .
    LY 541850
  • HY-107703
    CGP 39551

    		iGluR Neurological Disease
    CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity . CGP 39551 shows measurable inhibitory activity at both L-[ 3H]-glutamate (Ki=8.4 μM) .
    CGP 39551
  • HY-100806S
    Kynurenic acid-d5

    Quinurenic acid-d5

    		 Isotope-Labeled Compounds iGluR Endogenous Metabolite Apoptosis CXCR GPR35 Neurological Disease Inflammation/Immunology Endocrinology
    Kynurenic acid-d5 is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8[1][2].
    Kynurenic acid-d5
  • HY-100806R
    Kynurenic acid (Standard)

    Quinurenic acid (Standard)

    		 iGluR Endogenous Metabolite Apoptosis CXCR GPR35 Neurological Disease Inflammation/Immunology Endocrinology
    Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
    Kynurenic acid (Standard)
  • HY-103111
    MMPIP hydrochloride

    		mGluR Neurological Disease
    MMPIP hydrochloride is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP hydrochloride acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP hydrochloride alleviates pain and normalizes affective and cognitive behavior in neuropathic mice .
    MMPIP hydrochloride
  • HY-107503
    MMPIP

    		mGluR Neurological Disease
    MMPIP is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP alleviates pain and normalizes affective and cognitive behavior in neuropathic mice .
    MMPIP
  • HY-110146
    XAP044

    		mGluR Neurological Disease
    XAP044 is a potent and selective antagonist of mGlu7. The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic regulator of neurotransmission in the mammalian CNS. XAP044 demonstrates good brain exposure and wide spectrum anti-stress and antidepressant- and anxiolytic-like efficacy in rodent behavioral paradigms .
    XAP044
  • HY-17412R
    Minocycline hydrochloride (Standard)

    		Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Minocycline (hydrochloride) (Standard) is the analytical standard of Minocycline (hydrochloride). This product is intended for research and analytical applications. Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .
    Minocycline hydrochloride (Standard)
  • HY-70059
    LY341495
    5+ Cited Publications

    		 mGluR Neurological Disease
    LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively .
    LY341495
  • HY-N6776
    Penitrem A

    		Potassium Channel Neurological Disease Cancer
    Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective BK channel antagonist with antiproliferative and anti-invasive activities against multiple malignancies. Penitrem A increases the spontaneous release of endogenous glutamate, gamma-aminobutyric acid (GABA) and aspartate from cerebrocortical synaptosomes, and induces tremorgenic syndromes in animals .
    Penitrem A
  • HY-N0215
    L-Phenylalanine
    1 Publications Verification

    Phenylalanine

    		 Calcium Channel iGluR Endogenous Metabolite Metabolic Disease
    L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca + channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .
    L-Phenylalanine
  • HY-N0215S6
    DL-Phenylalanine-d5 hydrochloride

    2-Amino-3-phenylpropionic acid-d5 hydrochloride

    		 Isotope-Labeled Compounds Calcium Channel iGluR Endogenous Metabolite Metabolic Disease
    DL-Phenylalanine-d5 (hydrochloride) is the deuterium labeled DL-Phenylalanine hydrochloride. L-Phenylalanine hydrochloride is an essential amino acid isolated from Escherichia coli. L-Phenylalanine hydrochloride is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine hydrochloride is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine hydrochloride is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
    DL-Phenylalanine-d5 hydrochloride
  • HY-122218
    JHU-083
    4 Publications Verification

    		 Glutaminase Neurological Disease
    JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b + cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals .
    JHU-083
  • HY-120970
    Bis(7)-tacrine dihydrochloride

    		Cholinesterase (ChE) GABA Receptor iGluR Neurological Disease
    Bis(7)-tacrine dihydrochloride is a dimeric AChE inhibitor derived from tacrine. Bis(7)-tacrine dihydrochloride prevents glutamate-induced neuronal apoptosis by blocking NMDA receptors. Bis(7)-tacrine dihydrochloride is a potent GABAAreceptor antagonist. Bis(7)-tacrine dihydrochloride has the potential for the research of Alzheimer's disease .
    Bis(7)-tacrine dihydrochloride
  • HY-30004
    1-Aminocyclopropane-1-carboxylic acid

    		Endogenous Metabolite Metabolic Disease
    1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid protects neuron cells from death in in vivo ischemia models by moderately activating NMDA receptors. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .
    1-Aminocyclopropane-1-carboxylic acid
  • HY-19742A
    Lecozotan hydrochloride

    SRA-333 hydrochloride

    		 5-HT Receptor Neurological Disease
    Lecozotan (SRA-333) hydrochloride is an orally active and selective antagonist of 5-HT1A with a Ki of 4.5 nM for cloned human 5-HT1A receptor. Lecozotan hydrochloride enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. Lecozotan hydrochloride has the potential for mild-to-moderate Alzheimer's disease (AD) research .
    Lecozotan hydrochloride
  • HY-17387
    (-)-Huperzine A
    3 Publications Verification

    Huperzine A

    		 Cholinesterase (ChE) Apoptosis iGluR Neurological Disease
    (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .
    (-)-Huperzine A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: